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less. Conclusions: This analysts confirms that overweight and obese pts having PCI are 
at lower risk for in-hospital adverse events and mortality at one year. Our data suggest 
that, within this heterogeneous group, current smokers and those with severe non-car- 
diac disease are especially at risk following PCI. 
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Background: Brachytherapy has demonstrated benefit for in-stent restenosis, but results 
in patients with chronic total occlusions have not been reported. The objective of this 
study is to describe outcomes following brachytherapy in patients with chronic total 
occlusions. 
Methods: Of 746 patients treated in the GAMMA I, GAMMA 2, and SCRIPPS Ill studies, 
a total of 89 (11.9%) had chronic total occlusions. All patients received brachytherapy 
after angioplasty with or without stenting for in-stent restenosis. 
Results: The two groups were well matched with respect to baseline characteristics. Out- 
comes for the two groups are aisplayed below. 
Conclusion: Treatment of chronic in-stent total occlusions with brachytherapy is associ- 
ated with late target vessel revascularization rates similar to patients without total occlu- 
sions. The presence of a chronic total occlusion should not be considered an obstacle for 
brachytherapy. 
Excluding smokers and patients with severe concomitant disease Table I 
(n = 457) 
In-hospital death’ 2.1% 
In-hospital Ml 4.3% 
One-year death * 4.7% 
(n = 963) (n = 749) 
0.5% 0.7% 
3.1% 1 .9% 
3.2% 2.3% 
Total Occlusion Non-Total Occlusion Relative Risk 
[95%C.I.] 
In-Hospital Death 
MI/‘i-VR 
3.4% (3/89) 2.3% (15/657) 1.48 [0.44,5.00] 
*** p<=o.o01; ** p<o.o1; * p<o.o5 
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Late Thrombosis 1.1% (l/87) 1.6% (101639) 
(31.270) 
NR 25.3% (22/87) 30.4% (194/639) 
Cardia Death 4.6% (4/87) 1.6% (10/639) 
Myocardial Infarction 6.9% (6/87) 8.4% (561640) 
Death/Ml/lVR 32.2% (28187) 35.2% (2251640) 
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BACKGROUND: Brachytherapy is currently the only modality with proven efficacy for 
instent restenosis, but failure rates after brachytherapy approximate 25%. The sirolimus- 
eluting Bx VELOCITY(tm) stent has shown promising results for de nova coronary stano- 
sis. however its efficacy in the setting of in-stent restenosis and failed brachylherapy is 
unknown. 
METHODS: Sirolimus-eluting stents were implanted under a compassionate use protocol 
in 40 patients who restenosed following treatment with brachytherapy. Patients were 
treated at 5 study sites: Scripps Clinic, Lenox Hill Hospital, the University of Florida 
Health Science Center, Riverside Methodist Hospital, and the Providence Health Sys- 
tem. Baseline characteristics collected include general demographics, lesion and proce- 
dural data. Per protocol, all patients with failed brachytherapy are scheduled for 8 month 
follow up angiograms, which will be completed by February, 2003. 
RESULTS: 
Background: lntracoronary brachytherapy has been proven efficacious in the treatment 
of in-stent restenosis, but the results in older patients have not been characterized. The 
objective of this report is to evaluate outcomes followlng coronary brachytherapy in 
patients 275 years of age. 
Methods: Of the 746 patients treated in GAMMA 1, GAMMA 2, and SCRIPPS Ill trials, a 
total of 115 patients (15.4%) were 2 75 years of age. All received intracoronary gamma 
radiation after angioplasty with/without stenting for in-stent restenosis. 
Results: The two groups were well matched with respect to history of myocardial infarc- 
tion, diabetes, and hypertension. There was a higher incidence of smoking in the 
younger cohort (49.4% vs 35.7%, relative risk 1.39 [1.07.1.79]). There was a lower rate 
of previous bypass surgery (34.8% vs 46.5%, relative risk 0.75 [0.60,0.94]), and less vein 
graft interventions as the index procedure (10.0% vs 17.5% relative risk 0.57 [0.36,0.91]) 
in the younger group. Outcomes of the two groups are displayed below. 
Conclusions: lntracoronay gamma radiatron is associated with less target vessel revas- 
cularization in older patients. It should be considered a viable therapy in this patient 
group, especially considering the increased surgical morbidity and mortality in this chal- 
lenging patient population. 
Table 
Baseline Demographics and Angiogmphlc Characteristics 
Number of 
Patients 
Mean Age 
Male 
Prior Ml 
Prior PTCA 
Prior CABG 
40 Hyperlipidemia 37(93% RVD(visual) 2.94m 
) m 
63 years Hypertension 34(85% Lesion Length 16.8m 
) (visual) m 
31(78%) Angina 37(93% LAD 26(33% 
1 ) 
20(50%) Unstable Angina 6(16%) RCA 22(28% 
) 
4O(lcnl Stable Angina 31(84% SVG 8(10%) 
%) ) 
16(40%) Number Of 78 LCX 8(10%) 
Lesions 
Age< 75 Age 275 Relative Risk 
[95% Cl.) 
In-hospital DeathlMIflVR 2.2% (141613) 3.5% (4/l 15) 0.64 [0.21,190] 
Late thrombosis (31-270 days) 2.0% (12/613) 0.0% (O/l 13) 4.64 [0.28,77.84] 
Target vessel revascularization 31.3% (192/613) 21.2% (241113) 1.47 [1.01,2.14] 
Cardiac death 1.8% (11/613) 2.7% (3/l 13) 0.68 [0.19.2.38] 
Myocardial infarction 9.0% (55/613) 4.4% (51114) 2.05 [0.84,5.00] 
Death/MI/TVR 36.1% (221/613) 28.1% (32/114) 1.28 [0.94,1.75] 
iiza-181 Time Course of Stent Endothelialization After 
Intravascular Radiation Therapy 
Diabetes 
Smoking Hx 
12(30%) Lesions/Patient 1.95 LM 5(6%) 
20(50%) StentslPatients 2.58 Other Artery 7(9%) 
Treated 
CONCLUSIONS: An initial series of patients who failed brachytherapy and who are at 
high risk for recurrent restenosis have been treated with a sirolimus-eluting stent. Follow- 
up clinical and angiographic outcomes will be presented 
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Background: Late total occlusion after vascular brachytherapy (VBT) continues to be a 
serious complication of the technology. Delayed re-endothelialization was suggested as 
a pivotal cause for this phenomenon, however the time course for complete healing is 
unknown. Assessing the rate of healing following VBT can be helpful in determining the 
risk of late thrombosis and duration of antiplatelet therapy. 
Methods and results: Seventy-two rabbit iliac arteries underwent stent implantation, 
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0.73 [0.10,5.67] 
0.83 [0.57,1.22] 
2.94 [0.94,9.17] 
0.82 [0.36,1.84] 
0.92 [0.66,1.26] 
